Enanta Pharmaceuticals Initiates a Phase IIb Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. announced the initiation of a Phase IIb, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus infection who are at high risk of complications.